Drugs / Alogabat
Alogabat
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03847987 | Mar → Apr 2019 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03774576 | Dec 2018 → Mar 2019 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03507569 | Apr → Jun 2018 | autism spectrum disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT05630066 | Jul 2023 → Dec 2025 | Angelman syndrome | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT04299464 | Mar 2021 → May 2024 | autism spectrum disorder | Hoffmann-La Roche | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alogabat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05630066 ↗ |
| Known as | RG-7816 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095259 ↗ |
| Known as | RO7017773 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03507569 ↗ |
| Modality | Small molecule | — CHEMBL5095259 ↗ |
| Route | Oral | “administered orally” NCT03507569 ↗ |